Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Basilea Pharmaceutica AG, Allschwil

BSLN.S ✓ COMPLIANTFree checks used up today ☆ Track — members

Europe · Healthcare · Biotechnology & Medical Research ·

Switzerland Small Cap Analyst: BUY

Last Close

$83.71

▲ +3.76%

Market Cap $1.12B · Vol 87.08K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

18.01

FWD: 16.69

Market Cap

$1.12B

Small Cap

Div Yield

N/A

Annual dividend

EPS Growth

+32.26%

YoY

RSI (14)

63.80

Momentum

Beta

0.36

vs Market

52W High

$83.71

3.18% below

52W Low

$54.23

45.34% above

Volume

87.08K

Avg 57.50K

P/B

5.26

Price-to-book

ROE

38.52%

Return on equity

Free Float

99.33%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Basilea Pharmaceutica AG, Allschwil (BSLN.S) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does BSLN.S pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+6.98%

+27.31%

+36.90%

+34.24%

YTD

+26.14%

+49.84%

+64.73%

+43.09%

Financials & Valuation

TTM · Annual

Total Revenue	$293.30M
Net Income	$50.79M
Revenue Growth (YoY)	+14.46%
Gross Margin	83.08%
Operating Margin	22.18%
Net Profit Margin	17.32%
ROE	38.52%
ROA · ROIC	17.00% · 22.56%

P/E Ratio	18.01
Forward P/E (FY1)	16.69
PEG Ratio	-0.39
P/S	3.22
P/B	5.26
P/FCF	12.64
EPS Growth	+32.26%
Outstanding Shares	13.44M

Technical Indicators

50-Day SMA	$70.36
200-Day SMA	$66.20
RSI (14)	63.80
Beta	0.36
52-Week High	$83.71
52-Week Low	$54.23

Volume Today	87.08K
Avg Daily Volume (30D)	57.50K
Relative Volume	1.51x
Volatility (10D)	34.41
Volatility (30D)	39.37
Free Float	99.33%

Analyst Consensus

BUY

Current Price $83.71

Mean Target $123.19

52W Low$54.23 52W High$83.71

Current

Target

$54.23 $83.71

Current Analyst target

+47.16% upside potential · 7 analysts

Identifiers

ExchangeEurope

FIGIBBG001SCQ314

ISINCH0011432447

CountrySwitzerland

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateFeb 15, 2027

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG +1.23% ONC BeOne Medicines AG +1.55% 068270.KS Celltrion, Inc. +1.75% ABVX Abivax SA +4.66% ABVX.PA Abivax SA +3.59%

Company Profile

Basilea Pharmaceutica AG Allschwil, formerly known as Basilea Pharmaceutica AG, is a Switzerland-based commercial-stage biopharmaceutical company. The Company operates in one segment, which is the discovery, development, and commercialization of pharmaceutical products to meet the needs of patients with severe bacterial and fungal infections. It launched two hospital brands, Cresemba, which is an intravenous and oral drug for the treatment of invasive fungal infections, and Zevtera, which is an intravenous antibiotic for the treatment of severe bacterial infections, especially pneumonia. Additionally, the Company has several preclinical anti-infective assets in their portfolio. Company's products are present in United States, Canada, Europe, Asia, and Africa.